What factors drove the changes in InspireMD's revenue and profit?

What is the market's earnings forecast for InspireMD next quarter?

What is InspireMD's latest dividend and current dividend yield?

What does InspireMD do and what are its main business segments?

What were the key takeaways from InspireMD's earnings call?

What is the revenue and EPS growth rate for InspireMD year over year?

What were the key takeaways from InspireMD’s earnings call?

Did InspireMD beat or miss consensus estimates last quarter?

- **Revenue Growth**: Q4 2025 revenue up 62% YoY to $3.1 million, driven by U.S. CGuard Prime launch.
- **U.S. Momentum**: 500+ cases completed, 200+ centers in pipeline, 70% gross margin.
- **2026 Outlook**: $13-15 million revenue (45-65% growth), H2 acceleration with TCAR approval.
- **Clinical Progress**: C-GUARDIANS II data in April, TCAR indication Q3, enhanced delivery system Q4.

**【CEO Opening Remarks】**
- Q4 2025 revenue: $3.1 million (62% YoY growth), driven by CGuard Prime U.S. launch and international expansion.
- U.S. revenue: $866,000 (74% sequential growth), with gross margin of 70%.
- Completed over 500 CGuard Prime cases in the U.S., with 200+ centers in pipeline.
- 2026 guidance: $13-15 million revenue, 45-65% YoY growth, fueled by TCAR indication and enhanced delivery system.

**【CFO Financial Commentary】**
- Q4 2025 financials:
  - Total revenue: $3.1 million (62% YoY growth)
  - U.S. revenue: $866,000 (74% sequential growth)
  - International revenue: $2.3 million (17% YoY growth)
  - Gross profit: $1.2 million (37.5% of revenue)
  - Net loss: $11.8 million (improved from $9.2 million YoY)
  - Cash: $54.2 million (up from $34.6 million YoY)
- 2026 outlook: Sequential revenue acceleration in H2, driven by TCAR FDA approval and CAS delivery system enhancements.

**【Q&A Highlights】**
- **U.S. Adoption Metrics**:
  - 80+ centers completed cases, 200+ in pipeline
  - 30+ commercial team members, half hired in Q4 2025
  - Average 15-20 cases/year per physician
- **Product Development**:
  - Next-gen delivery system launch Q4 2026
  - FDA 30-day review for minor delivery system changes
- **Clinical Trials**:
  - C-GUARDIANS II interim data at Charing Cross (April 2026)
  - TCAR indication expected Q3 2026
  - SwitchGuard TCAR Neuroprotection clearance Q2 2027

InspireMD, Inc.(NSPR)-20260318-2025 Q4 Earnings call transcript

- **Revenue Surge**: Q3 2025 revenue up 39% to $2.5M, driven by U.S. CGuard Prime launch and global expansion.
- **Clinical Impact**: Over 100 U.S. cases, 70k+ global stents sold, with tandem lesion study 50% enrolled.
- **Financial Strength**: 34.2% gross margin, $63.4M cash from financing, positioning for Q4 growth to $2.5-3.0M.
- **Strategic Moves**: New CMO, deliberate U.S. onboarding (12 reps, 12+ accounts), and premium pricing for broad adoption.

### CEO Summary Section
- **Revenue Growth**: Total revenue increased by 39% to $2.5 million, driven by the U.S. launch of CGuard Prime and international expansion. U.S. revenue reached $497,000 in the first quarter post-FDA approval.
- **Product Adoption**: Over 100 CGuard Prime cases performed in the U.S., with strong demand in large IDNs. Global stent sales exceeded 70,000 units, reflecting a shift to stent-first carotid intervention.
- **Clinical Momentum**: Enrollment over 50% complete in the tandem lesion study with Dr. Adnan Siddiqui. C-GUARDIANS II and III trials advancing TCAR solutions, targeting FDA clearance in mid-2027.
- **Team Expansion**: Hired Dr. Peter Soukas as Chief Medical Officer to strengthen clinical leadership and evidence-building.

### CFO Financial Commentary
- **Revenue Breakdown**: Q3 2025 revenue of $2.5 million (U.S.: $497k, International: $2.0 million). Gross margin improved to 34.2% (vs. 22.9% in Q3 2024) due to U.S. sales mix and cost leverage.
- **Financial Performance**: Net loss of $12.7 million, offset by $63.4 million in cash from a $40.1 million PIPE and $17.9 million milestone financing.
- **Outlook**: Q4 2025 revenue expected to grow sequentially to $2.5-3.0 million, with U.S. sales ramping and international stability.

### Q&A Highlights
- **Physician Feedback**: CGuard Prime praised for its balance of open/closed-cell design, reducing adverse events by 2-3x vs. first-gen stents. Priced at a modest premium to CAS/TCAR stents to enable broad adoption.
- **U.S. Launch Metrics**: 12+ sales reps activated, over a dozen accounts opened, and 100+ cases performed in 3 months. ASP strategy focuses on sustainable volume growth.
- **Sales Force Strategy**: 30+ U.S. commercial team members, with plans to scale based on Q4 2026 case volume trends.

InspireMD, Inc. (NSPR) Q3 2025 Earnings Call Transcript

- **Breakthrough Launch**: CGuard Prime FDA approval in June 2025, with early U.S. adoption surpassing expectations, including double-digit physician procedures and stocking orders.
- **Financial Fortification**: Secured $58 million in funding, enhancing U.S. commercial scale and clinical pipeline execution.
- **Clinical Expansion**: SwitchGuard TCAR system now expected for 2027 clearance, aligning with evolving regulatory requirements.
- **Market Leadership**: 60,000+ global implants and U.S. claims data-driven targeting of 4,000+ high-volume physicians, positioning for CAS/TCAR market share growth.

**【CEO Summary Section】**
- **FDA Approval and Launch Momentum**: Received FDA premarket approval for CGuard Prime in late June 2025, commencing U.S. commercial launch. Early adoption has been strong, with double-digit physicians performing procedures and stocking orders secured in multiple accounts.
- **Clinical Pipeline Progress**: 
  - C-GUARDIANS II TCAR study enrollment progressing, targeting 2026 FDA clearance.
  - C-GUARDIANS III TCAR study with SwitchGuard neuroprotection system now expected for 2027 clearance due to regulatory and development complexities.
  - Acute stroke tandem lesion study with Dr. Adnan Siddiqui nearing halfway enrollment.
- **Financial Strength**: Secured $58 million in gross proceeds through a private placement and warrant exercises, bolstering U.S. commercial operations and long-term growth.

**【CFO Financial Commentary】**
- **Q2 2025 Financials**: 
  - Total revenue: $1.8 million (2% YoY increase), driven by international adoption and FX gains, offset by U.S. pre-launch timing.
  - Gross profit: $313,000 (17.6% margin), down 5.7% YoY due to production variances.
  - Operating expenses: $13.3 million (55% YoY increase) for U.S. commercial team expansion and HQ setup.
  - Net loss: $13.2 million ($0.26/share), reflecting pre-launch investments.
  - Cash balance: $19.4 million as of June 30, excluding recent $58 million financing.

**【Q&A Highlights】**
- **Commercial Momentum**: 
  - U.S. sales team of 20+ field reps, targeting 10 additional hires by year-end.
  - 60,000+ annual CAS/TCAR procedures in the U.S., with 4,000+ performing physicians.
  - Early focus on high-volume accounts, with claims data guiding prioritization.
- **Market Trends**: 
  - CAS/TCAR mix approaching 50% of carotid interventions, up from <40% in 2024.
  - CMS shifts driving stent-first preference, aligning with CGuard Prime's implant-agnostic strategy.
- **SwitchGuard Timeline**: 
  - 2027 clearance reflects regulatory uncertainties and device development complexity, though team remains agile to accelerate timelines.


InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

- **CGuard Prime on Track for Q3 2025 U.S. Launch**: FDA approval expected in Q3, with Miami manufacturing facility operational for domestic production.
- **Q1 Revenue Growth 1.2% YoY**: $1.53 million driven by international markets, offset by FX and inventory management ahead of U.S. launch.
- **SwitchGuard TCAR Solution Targeting 2026 Clearance**: IDE resubmission complete, with late 2026 FDA clearance anticipated for fully integrated system.
- **C-GUARDIANS II Enrollment Strong**: 8 active sites demonstrate physician enthusiasm for CGuard Prime in TCAR procedures.
- **Operating Expenses Up 52.5% YoY**: Reflects U.S. sales force expansion and launch preparation costs.

**【CEO Opening Remarks】**
- Q1 2025 CGuard revenue reached $1.53 million, up 1.2% YoY, with 2,611 units sold. Cumulative implants now exceed 64,000 globally.
- CGuard Prime FDA approval expected in Q3 2025, with U.S. launch preparations underway. If Q1 international volume replicated in U.S., potential revenue of $12 million at current ASPs.
- CGuard Prime enrollment in C-GUARDIANS II pivotal study progressing well, with 8 active sites and strong physician enthusiasm.
- SwitchGuard Neuroprotection System IDE submission resubmitted, targeting late 2026 FDA clearance for fully integrated TCAR solution.
- Miami manufacturing facility operational, supporting U.S. production and supply chain diversification.

**【CFO Financial Highlights】**
- Q1 2025 total revenue: $1.53 million (+1.2% YoY), driven by existing market growth offset by FX and inventory management.
- Gross margin: 19.1% ($292k gross profit), flat YoY.
- Operating expenses: $11.8 million (+52.5% YoY), primarily due to U.S. sales force expansion, CGuard Prime launch prep, and Miami facility costs.
- Net loss: $11.2 million (-$0.22/share), vs. $7.0 million (-$0.21/share) in Q1 2024.
- Cash balance: $26.1 million as of March 31, 2025, down from $34.6 million at year-end.

**【Q&A Key Takeaways】**
- **FDA Approval Timeline**: Q3 2025 approval for CGuard Prime remains on track, with final feedback from February 2025 facility audit being addressed. FDA resource constraints have added prudent scheduling buffer.
- **Clinical Enrollment**: C-GUARDIANS II enrollment progressing well with 8 active sites. SwitchGuard IDE resubmission expected to clear in coming months, enabling late 2026 clearance.
- **Commercial Buildout**: U.S. sales team expanded to ~20 professionals, with hiring cadence aligned to regulatory timelines. Miami facility operational, supporting domestic production.
- **CREST-2 Trial**: Enrollment complete; results expected H2 2025. Industry consensus suggests limited practice impact, as less severe patients unlikely to benefit from intervention.

InspireMD (NSPR)-9 May 25-2025 Q1 Earnings call transcript

- **Revenue Momentum**: Q4 2024 CGuard revenue $1.95M (10.6% YoY), full-year $7M (13% YoY). Global units sold 12,100 annually, cumulatively >60,000 implants.
- **U.S. Launch Catalyst**: CGuard Prime U.S. approval expected H1 2025; potential $16M+ Q4 2024 sales if replicated in U.S. 1-year C-GUARDIANS data shows 1.95% adverse events (lowest ever reported).
- **Financial Milestones**: $17.9M second tranche of $113.6M private placement triggered upon FDA approval; $34.7M cash as of Dec 31, 2024.
- **Pipeline Progress**: C-GUARDIANS II TCAR trial enrolling well; C-GUARDIANS III SwitchGuard IDE to start Q2 2025, targeting 2H 2026 approval.
- **Commercial Build**: 13 new hires (4 directors, 9 reps) in Q4; 24-month expansion plan. Miami HQ ready for U.S. launch; 2025 focus on infrastructure, 2026+ on revenue growth.

**【CEO Summary Section】**
- Q4 2024 CGuard revenue reached $1.95 million, up 10.6% YoY, with full-year revenue of $7 million (13% YoY growth). Global units sold: 3,512 in Q4 and 12,100 annually, cumulatively over 60,000 implants.
- CGuard Prime U.S. launch on track for H1 2025. If Q4 global sales (3,512 units) replicated in U.S., potential revenue >$16 million, assuming CAS/TCAR mix at current ASPs.
- C-GUARDIANS pivotal trial 1-year data: 0.95% 30-day and 1.95% 12-month major adverse events (lowest ever reported in carotid stent trial). FDA PMA submission complete; interactive review ongoing.
- Miami headquarters built to support U.S. launch. 12+ field sales professionals onboarded, with 24-month expansion plan. 
- $17.9M second tranche of $113.6M private placement triggered upon FDA approval; remaining milestones include SwitchGuard TCAR clearance and 4Q sales in 2026.
- C-GUARDIANS II TCAR trial enrolling well; C-GUARDIANS III IDE for SwitchGuard/CGuard Prime 80 expected to initiate Q2 2025.

**【CFO Financial Commentary】**
- Q4 2024: Revenue $1.9M (10.6% YoY), gross profit $0.47M (24.1% margin vs 28.7% YoY). Operating expenses $9.8M (55.8% YoY increase) due to U.S. launch prep (salaries, share-based comp). Net loss $9.1M.
- Full-year 2024: Revenue $7M (13% YoY), gross profit $1.5M (21.5% margin vs 29.1% YoY). Operating expenses $35M (52.5% YoY growth). Net loss $32M. Cash: $34.7M as of Dec 31, 2024.
- No forward guidance provided; expects to share U.S. revenue outlook post-FDA approval.

**【Q&A Highlights】**
- **FDA Approval Timing**: CEO confident in H1 2025 approval despite FDA macro challenges. Interactive review productive; no delays anticipated.
- **Clinical Trials**: C-GUARDIANS II TCAR trial on track for early 2026 commercial launch. C-GUARDIANS III SwitchGuard IDE expected to initiate Q2 2025, targeting 2H 2026 approval.
- **International vs U.S.**: OUS business strong, growing organically. U.S. launch in 2H 2025 will require foundational infrastructure build (VAC engagement, rep training). 2025 focus: U.S. readiness; 2026+: revenue acceleration.
- **Commercial Team**: 13 new hires (4 directors, 9 reps) in Q4; 24-month expansion plan. Shane Gleason: "all politics is local"—reps leveraging relationships to position for VAC consideration post-approval.
- **OpEx Growth**: CFO expects continued R&D and sales expenses growth (e.g., C-GUARDIANS II/III trials, PMA costs, rep hiring). No specific guidance, but "significant" OpEx expansion anticipated.

Actual							-3	-0.9	-0.6	-0.53	-0.15	-0.16	-0.21	-0.22	-0.16	-0.19	-0.22	-0.26	-0.17	-0.14
Forecast							-5.25	-1.2	-0.84	-0.68	-0.14	-0.19	-0.18	-0.19	-0.2	-0.195	-0.2	-0.26	-0.195	-0.1933
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+42.86%	+25.00%	+28.57%	+22.06%	-7.14%	+15.79%	-16.67%	-15.79%	+20.00%	+2.56%	-10.00%	0.00%	+12.82%	+27.57%

NSPR

NSPR fundamentals

NSPR Q4 2025 Earnings

Earnings Call

You can ask Aime

NSPR

NSPR fundamentals

NSPR Q4 2025 Earnings

Earnings Call

NSPR Earnings Call Summary for Q4/20258:30 AM on Mar 18, 2026

NSPR Earnings Call Summary for Q3/20258:30 AM on Nov 4, 2025

NSPR Earnings Call Summary for Q2/20258:30 AM on Aug 5, 2025

NSPR Earnings Call Summary for Q1/20258:30 AM on May 9, 2025

NSPR Earnings Call Summary for Q4/20248:30 AM on Mar 12, 2025

You can ask Aime